Abcam, ab258189, Human SIPA1 (Spa-1) knockout HeLa cell lysate

Size: 1Kit
SIPA1 KO cell lysate available now. KO validated by Western blot. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 182 bp deletion in exon5 and 1 bp deletion in exon5 and 4 bp deletion in exon5.
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Knockout validation:Sanger Sequencing,Western blot,
Mutation description:Knockout achieved by using CRISPR/Cas9, 182 bp deletion in exon5 and 1 bp deletion in exon5 and 4 bp deletion in exon5.,
Disease:Adenocarcinoma

Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-SIPA1, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Western blot, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Spa-1 also known as human SPA plays a role in the regulation of small GTPase activity specifically targeting Rap1. This protein weighing approximately 120 kDa resides within various tissues with notable expression in the hematopoietic system and neuronal tissues. Researchers use names like Anti-SPA and Anti-Spa when referring to assays designed to recognize this protein. SPA-1 functions as a Rap1 GTPase-activating protein (GAP) facilitating the conversion of active GTP-bound Rap1 to its inactive GDP-bound form.
Biological function summary
Spa-1 engages in the control of cell adhesion and migration through its interaction with the Ras-related protein Rap1. As part of larger signal transduction complexes Spa-1 influences the organization of actin cytoskeleton and impacts integrin-mediated cell adhesion. Through its GAP activity it maintains cellular responsiveness to external stimuli impacting processes like immune cell trafficking and neuronal growth. Studies have noted its significance in maintaining homeostasis in tissues where it is expressed.
Pathways
Spa-1 integrates into key signaling cascades impacting the Ras superfamily of GTPases. Within the Rap1 signaling pathway Spa-1 works alongside proteins like RapGEF to finely regulate signal transduction processes affecting cell adhesion and cytoskeletal dynamics. In the context of the integrin signaling pathway Spa-1 modulates the actions of B-Raf in connection with Rap1 dictating responses necessary for cellular motility and positioning.
Spa-1 displays relevance to leukemia and neurological conditions. Its role in negative regulation of Rap1 activity links it to the aberrant proliferation seen in certain leukemia types where altered Rap1 signaling contributes to uncontrolled cell growth. Furthermore disruptions in Spa-1's modulation of neuronal Rap1 activity have associations with neurodegenerative diseases where proper cell migration and adhesion are impaired. Research explores its connections to proteins like BCR-ABL in the context of leukemia highlighting Spa-1 as a therapeutic target in disease management.